Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $509000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed N/A to $509000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.0 million for FY2025, 1.51% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $509000.0 at Soleno Therapeutics, up from $502000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $509000.0 in Q4 2025, with the low at $502000.0 in Q2 2025.